Inhibrx (INBX) IPO Opens, Trades Higher

Today's IPO for Inhibrx Inc. (NASDAQ: INBX) opened for trading earlier at $22.10 after pricing 7,000,000 shares of common stock at a price to the public of $17.00 per share. All of the shares of common stock are being offered by Inhibrx. Shares have continued higher to $23.65.

In addition, Inhibrx has granted the underwriters a 30-day option to purchase up to 1,050,000 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions.

Jefferies, Evercore ISI and Credit Suisse are acting as joint book-running managers for the offering. LifeSci Capital is acting as co-manager for the offering.

Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The Inhibrx pipeline is focused on oncology and orphan diseases. Inhibrx has collaborations with Elpiscience, bluebird bio, Celgene and Chiesi.

You May Also Be Interested In

• Nscale targets up to $3B in US IPO as soon as September - Bloomberg
• MEXC Partners with Kaito on $200K Stock Education Campaign During MEXC 0808 Stock Season
• Benchmark Reiterates Buy Rating on Rank One Computing (ROC)